- Specialization
Biotechnologyand 1 more specialization valuesLess
- Scientific Discovery
- Business
Scientific Researchand 2 more business valuesLess
- AI Research
- Model Development
- Market
Healthcareand 1 more market valuesLess
- Life Sciences
- Ecosystem
- AI for science
- Customers
- Not classified
More details
- Organization type
- Commercial Company
- Ecosystem
- AI for science
- Business
- Scientific Research, AI Research, Model Development
- Specialization
- Biotechnology, Scientific Discovery
- Market
- Healthcare, Life Sciences
- Customers
- Not classified
- Delivery models
- Not classified
- Revenue models
- Not classified
- Listing status
- Not classified
- Latest equity round
- Not classified
- Reported funding amount
- Not classified
About
We’re an AI-native biotech, working on replacing needles with pills. Many drugs, like insulin or Ozempic, are wonderful except you have to inject them. We discover new molecules that you can take as a pill instead. Because the pills operate on biology which has been shown to be effective in people, rather than merely in animal models of disease, we avoid what has historically been the single biggest risk in drug discovery. This should dramatically increase our probability of success. There’s $200B of treatable diseases and validated human biology without a pill because discovery programs lack a tractable chemical starting point. This is a zero-shot inference problem, because these targets have no training data, so LLMs and other historical interpolative AI approaches are insufficient. Instead, we are building our own extrapolative frontier models that reason beyond their training data. Most critically, we have repeatedly validated our platform on both our own and partner programs. On 4 biologically- and structurally-diverse targets where we had zero training data, we successfully picked binders that were validated experimentally, with confirmation ranging from primary screen hits to crystallographic structures.
Recent News
Y Combinator’s Launch YC featured WonderTx’s public launch, presenting its AI-native drug-discovery approach and its initial aim of replacing injectable medicines with pill alternatives. The post describes using agentic processes to speed compound selection and cloud labs to scale the design loop.
Active Roles
0No active roles right now.
Get notified when they post